Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu] Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)

Loading...
Thumbnail Image

Authors

Ahmadzadehfar, Hojjat
Rahbar, Kambiz
Baum, Richard P.
Seifert, Robert
Kessel, Katharina
Bogemann, Martin
Kulkarni, Harshad R.
Zhang, Jingjing
Gerke, Carolin
Fimmers, Rolf

Journal Title

Journal ISSN

Volume Title

Publisher

Springer

Abstract

Please read abstract in the article.

Description

This article is part of the Topical Collection on Oncology - Genitourinary

Keywords

Radioligand therapy, Lu-PSMA, Chemotherapy, Castration-resistant prostate cancer (CRPC), Metastatic CRPC (mCRPC)

Sustainable Development Goals

Citation

Ahmadzadehfar, H., Rahbar, K., Baum, R.P. et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial) European Journal of Nuclear Medicine and Molecular Imaging, 48, 113–122 (2021). https://doi.org/10.1007/s00259-020-04797-9.